Identification of differential genetic profiles in severe forms of fibromyalgia and chronic fatigue syndrome/myalgic encephalomyelitis: A population-based genetic association study

Journal of Clinical Research

Volumn 11, Issue 1-24, 2008, Pages 1-24

  Garcia Fructuoso, Ferran J ^a   Lao Villadoniga, Jose Ignacio ^b   Santos, Cristina ^c   Poca Dias, Violant ^a   Fernandez Sola, Joaquim ^d  

^a Centro Internacional de Medicina Avanzada   (Spain)

^b Molecular Genetics Department   (Spain)

^c UNIVERSITY OF THE AZORES   (Portugal)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Chronic fatigue syndrome; Fibromyalgia; Myalgic encephalomyelitis; Single nucleotide polymorphism; SNP

Indexed keywords

ADULT; ARTICLE; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FIBROMYALGIA; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC MARKER; HAPLOTYPE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; POPULATION RESEARCH; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 43749102463     PISSN: 13695207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Kennedy G, Abbot NC, Spence V et al. The specificity of the CDC-1994 criteria for chronic fatigue syndrome: comparison of health status in three groups of patients who fulfill the criteria. Annals of Epidemiology 2004; 14: 95-100.
2. Birtane M, Uzunca K, Tastekin N et al. The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis by using SF-36 Health Survey. Clinical Rheumatology 2007; 26: 679-684.
3. Buchwald D. Fibromyalgia and chronic fatigue syndrome: similarities and differences. Rheumatic Diseases Clinics of North America 1996; 22: 219-243.
4. Evengard B, Nilsson CG, Lindh G et al. Chronic fatigue syndrome differs from fibromyalgia. No evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome. Pain 1998; 78: 153-155.
5. Bradley LA, Kendree-Smith NL, Alarcon GS. Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome. Current Review of Pain 2000; 4: 148-157.
6. Wolfe F, Ross K, Anderson J et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis and Rheumatism 1995; 38: 19-28.
7. Prins JB, van der Meer JW, Bleijenberg G. Chronic fatigue syndrome. Lancet 2006; 367: 346-355.
8. Carruthers BM, Jain AK, De Meirleir KL et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. Journal of Chronic Fatigue Syndrome 2003; 11: 7-115.
9. Reeves W-C, Wagner D, Nisenbaum R et al. Chronic fatigue syndrome - a clinically empirical approach to its definition and study. BMC Medicine 2005; 3: 19.
10. Jason LA, Corradi K, Torres-Harding S et al. Chronic fatigue syndrome: the need for subtypes. Neuropsychology Review 2005; 15: 29-58.
11. Smith AK, White PD, Aslakson E et al. Polymorphisms in genes regulating the HPA axis associated with empirically delineated classes of unexplained chronic fatigue. Pharmacogenetics 2006; 7: 387-394.
12. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. Journal of Rheumatology 1991; 18: 728-733.
13. Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clinical and Experimental Rheumatology 2005; Suppl 39: S154-S162.
14. Wagner D, Nisenbaum R, Heim C et al. Psychometric properties of the CDC Symptom Inventory for assessment of chronic fatigue syndrome. Population Health Metrics 2005; 3: 8.
15. Goldenberg DL. Office management of fibromyalgia. Rheumatic Diseases Clinics of North America 2002; 28: 437-446.
16. Hamilton WT, Gallagher AM, Thomas JM et al. The prognosis of different fatigue diagnostic labels: a longitudinal survey. Family Practice 2005; 22: 383-388.
17. Sachidanandam R, Weissman D, Schmidt SC et al; International SNP Map Working Group. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409: 928-933.
18. Gray IC, Campbell DA, Spurr NK. Single nucleotide polymorphisms as tools in human genetics. Human Molecular Genetics 2000; 9: 2403-2408.
19. Wolfe F, Smythe HA, Yunus MB et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis and Rheumatism 1990; 33: 160-172.
20. Fukuda K, Straus SE, Hickie I et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Annals of Internal Medicine 1994; 121: 953-959.
21. Okifuji A, Turk DC, Sinclair JD et al. A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome. Journal of Rheumatology 1997; 2: 377-383.
22. Carville SF, Arendt-Nielsen S, Bliddal H et al. EULAR evidence based recommendations for the management of fibromyalgia syndrome. Annals of the Rheumatic Diseases 2007; Oct 3 [Epub ahead of print].
23. Cocchiarella L, Andersson GBJ. Guides to the Evaluation of Permanent Impairment, 5th edn. Chicago, IL: American Medical Association Press, 2001.
24. Cusco-Segarra AM, Garcia-Fructuoso FJ, Lopez-Crespi F et al. Computer-assisted cognitive function assessment in fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity patients. 8th International Association for CFS/ME (IACFS/ME) Conference on Chronic Fatigue Syndrome, Fibromyalgia and other Related Illnesses; Fort Lauderdale, FL, 10-14 January 2007.
25. Reeves WC, Lloyd A, Vernon SD et al; International Chronic Fatigue Syndrome Study Group. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Services Research 2003; 3: 25.
26. Garcia-Fructuoso FJ, Lao-Villadoniga JI, Beyer K et al. Relationship between COMT gene genotypes and severity of fibromyalgia. Rheumatologia Clinica 2006; 2: 168-172.
27. Cacace E, Ruggiero V, Anedda C et al. Quality of life and associated clinical distress in fibromyalgia. Reumatismo 2006; 58: 226-229.
28. Tobler AR, Short S, Andersen MR et al. The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. Journal of Biomolecular Techniques 2005; 16: 398-406.
29. Gursoy S, Erdal E, Herken H et al. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatology International 2003; 23: 104-107.
30. Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of fibromyalgia syndrome. Pharmacogenomics 2007; 8: 67-74.
31. Goertzel BN, Pennachin C, de Souza CL et al. Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome. Pharmacogenomics 2006; 7: 475-483.
32. Rajeevan MS, Smith AK, Dimulescu I et al. Glucocorticoid receptor polymorphisms and haplotypes associated with chronic fatigue syndrome. Genes, Brain, and Behavior 2006; 6: 167-176.
33. Wood PB, Patterson II JC, Sunderland JJ et al. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. Journal of Pain 2007; 8: 51-58.
34. Lawson K. Emerging pharmacological therapies for fibromyalgia. Current Opinion in Investigational Drugs 2006; 7: 631-636.
35. Wallace DJ. Is there a role for cytokine based therapies in fibromyalgia. Current Pharmaceutical Design 2006; 12: 17-22.
36. Wood PB. A reconsideration of the relevance of systemic low-dose ketamine to the pathophysiology of fibromyalgia. Journal of Pain 2006; 7: 611-614.
37. Carlson CS, Eberle MA, Rieder MJ et al. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. American Journal of Human Genetics 2004; 74: 106-120.
38. Andy F. Regression. In: Discovering Statistics Using SPSS for Windows: advanced techniques for beginners, 1st edn. London, UK: Sage Publications Ltd., 2000; 103-201.
39. Hoh J, Wille A, Ott J. Trimming, weighting, and grouping SNPs in human case-control association studies. Genome Research 2001; 11: 2115-2119.
40. Dawson J, Belkhir K. A Bayesian approach to the identification of panmictic populations and the assignment of individuals. Genetical Research 2001; 78: 59-77.
41. Balding DJ. A tutorial on statistical methods for population association studies. Nature Reviews. Genetics 2006; 7: 781-791.
42. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843.
43. Buskila D. Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Current Opinion in Rheumatology 2001; 3: 117-127.
44. White KP, Speechley M, Harth M, Ostbye T. Co-existence of chronic fatigue syndrome with fibromyalgia syndrome in the general population. A controlled study. Scandinavian Journal of Rheumatology 2000; 29: 44-51.
45. Fagan TJ. Letter: Nomogram for Bayes theorem. New England Journal of Medicine 1975; 293: 257.
46. Janssens AC, van Duijin CM. Towards predictive genetic testing of complex diseases. European Journal of Epidemiology 2006; 21: 869-870.
47. Salido M, Navarro P, Judez P et al. Factors related to temporal incapacity in patients with fibromyalgia. Rheumatology Clinics 2007; 3: 67-72.
48. Cacace E, Ruggiero V, Anedda C et al. Quality of life and associated clinical distress in fibromyalgia. Reumatismo 2006; 58: 226-229.
49. Coetzer P, Lockyer I, Comm B et al. Assessing impairment and disability for syndromes presenting with chronic fatigue. Journal of Disability Medicine 2003; 3: 16-26.